Castration Resistant Prostate Cancer: Clinical Insights from a US Oncologists' Survey

Date: March 22, 2011
Pages: 24
Price:
US$ 2,999.00 US$ 500.00
License [?]:
Publisher: The Assessment Group
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CCD647398B4EN
Leaflet:

Download PDF Leaflet

Castration Resistant Prostate Cancer: Clinical Insights from a US Oncologists' Survey
Progressively unfolding patient situation, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment and testing choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients.

This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of patients with advanced prostate cancer.

Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new information and products impacting oncologists’ decisions. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:
  • Understand what occurs with actual patients
  • Access the most up-to-date prescribing trends
  • Gain actionable data for developing and improving your market strategies
  • Pinpoint needs of your target audience
  • Focus resources to maximize the effectiveness of your budget
  • Understand where your product fits
  • Understand where your competitor’s product fits
  • Design messages to advance brand performance
Executive Summary:

CHAPTER 1: INTRODUCTION

Table 1. Treatment Options in Advanced Prostate Cancer

CHAPTER 2: RESPONDENT DEMOGRAPHICS

Table 2.1 Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years Since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by States
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen

CHAPTER 3: ELDERLY PATIENT TREATED FOR GLEASON’S 7 ADENOCARCINOMA, INCREASED PSA 18 MONTHS LATER

Figure 3.1 Barriers to optimal treatment
Figure 3.2 Confidence in treating to optimal outcome
Figure 3.3 Treatment following rising PSA on leuprolide
Figure 3.4 Treatment decision upon disease progression
Figure 3.5 Factors that influenced treatment
Table 3.1 Factors that influenced treatment by types of agents selected
Figure 3.6 Other agents that would be appropriate to include in therapy
Figure 3.7 Treatment upon rising PSA
Figure 3.8 Treatment upon further disease progression

CHAPTER 4. PATIENT WITH GLEASON’S 3+4 ADENOCARCINOMA AND MULTIPLE METASTASES TO PELVIS AND SPINE DEVELOPS CASTRATION-RESISTANT DISEASE.

Figure 4.1 Treatment Choices
Figure 4.2 Confidence in treating to optimal outcome
Figure 4.3 Cycles of docetaxel that the patient should receive
Figure 4.4 Option to Continue LHRH agonist
Figure 4.5 Factors Associated with Continuing LHRH Agonist
Figure 4.6 Next Therapy with Good Performance Status upon Progressing after Docetaxel

CHAPTER 5: SUMMARY

APPENDIX A: SURVEY INSTRUMENT
Skip to top


Ask Your Question

Castration Resistant Prostate Cancer: Clinical Insights from a US Oncologists' Survey
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: